<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825548</article-id>
    <article-id pub-id-type="pmid">36243971</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac860</article-id>
    <article-id pub-id-type="publisher-id">gkac860</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MeDBA: the Metalloenzyme Data Bank and Analysis platform</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Jun-Lin</given-names>
        </name>
        <aff><institution>Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University</institution>, Chengdu, Sichuan 610041, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Song</given-names>
        </name>
        <aff><institution>National Clinical Research Center for Geriatrics and Department of Periodical Press, West China Hospital, Sichuan University</institution>, Chengdu, Sichuan 610041, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Cong</given-names>
        </name>
        <aff><institution>Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University</institution>, Chengdu, Sichuan 610041, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dai</surname>
          <given-names>Qing-Qing</given-names>
        </name>
        <aff><institution>Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University</institution>, Chengdu, Sichuan 610041, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Schofield</surname>
          <given-names>Christopher J</given-names>
        </name>
        <aff><institution>Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, Chemistry Research Laboratory, Mansfield Road, University of Oxford</institution>, Oxford OX1 3TA, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4915-6677</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Guo-Bo</given-names>
        </name>
        <!--liguobo@scu.edu.cn-->
        <aff><institution>Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University</institution>, Chengdu, Sichuan 610041, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 135 5016 1826; Email: <email>liguobo@scu.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-10-16">
      <day>16</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D593</fpage>
    <lpage>D602</lpage>
    <history>
      <date date-type="accepted">
        <day>27</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>14</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>07</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac860.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Metalloenzymes are attractive research targets in fields of chemistry, biology, and medicine. Given that metalloenzymes can manifest conservation of metal-coordination and ligand binding modes, the excavation and expansion of metalloenzyme-specific knowledge is of interest in bridging metalloenzyme-related fields. Building on our previous metalloenzyme-ligand association database, MeLAD, we have expanded the scope of metalloenzyme-specific knowledge and services, by forming a versatile platform, termed the Metallo<italic toggle="yes">e</italic>nzyme Data Bank and Analysis (MeDBA). The MeDBA provides: (i) manual curation of metalloenzymes into different categories, that this M-I, M-II and M-III; (ii) comprehensive information on metalloenzyme activities, expression profiles, family and disease links; (iii) structural information on metalloenzymes, in particular metal binding modes; (iv) metalloenzyme substrates and bioactive molecules acting on metalloenzymes; (v) excavated metal-binding pharmacophores and (vi) analysis tools for structure/metal active site comparison and metalloenzyme profiling. The MeDBA is freely available at <ext-link xlink:href="https://medba.ddtmlab.org" ext-link-type="uri">https://medba.ddtmlab.org</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82122065</award-id>
        <award-id>82073698</award-id>
        <award-id>81874291</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sichuan Science and Technology Program</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022YFH0027</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>111 Project</institution>
            <institution-id institution-id-type="DOI">10.13039/501100013314</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>B18035</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Cancer Research UK</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000289</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Biotechnological and Biological Research Council</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Metal ions are indispensable components of all living organisms. They play central roles in many biomedicinally important process, e.g. ferroptosis (<xref rid="B1" ref-type="bibr">1</xref>) and copper-induced cell death (<xref rid="B2" ref-type="bibr">2</xref>) amongst many others, and are functionally required adjuncts for a myriad of biological macromolecules. Metalloenzymes form an ubiquitous ensemble of enzymes that contain structurally and/or functionally important metal ions for bioactivity, structural, or signalling, or other reasons; more than one-third of all known enzymes are assigned as metalloenzymes. In a broader sense, nucleic acids with specific enzymatic functions (e.g. ribozymes and DNAzymes), which require one or more metal ions for activity, can also be categorized as metallo(en)zymes (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). Metalloenzymes have long been recognized as important in a variety of societally important and research fields. In synthetic biology, for example, functionally diverse artificial metalloenzymes have been developed, highlighting the potential to create new-to-nature biocatalytic transformations (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>). Owing to their critical roles in various biological processes and diseases, including as recently reported in immunotherapy (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>), metalloenzymes are important drug targets for therapeutic intervention. Although a number of new drugs or drug candidates for metalloenzymes have been established (<xref rid="B9" ref-type="bibr">9</xref>), most disease associations and therapeutic potentials for metalloenzymes remain largely unexploited, suggesting a vast space for drug discovery and development targeting metalloenzymes.</p>
    <p>Metalloenzyme-specific knowledge, such as the metal ion(s) involved in catalysis, coordination chemistry, and ligand interactions, has had impact beyond biological catalysis. For instance, a deep understanding of how [FeFe]-hydrogenases interconvert protons, electrons and dihydrogen at their unique iron-based active site, has advanced the design of new catalytically active metalloenzymes and nucleic acids (<xref rid="B4" ref-type="bibr">4</xref>). Atomistic understanding of the metal-ligand interactions has assisted in the discovery of new metallodrugs and metalloenzyme inhibitors (<xref rid="B10" ref-type="bibr">10–12</xref>). Coupled with the fast-growing body of experimental data regarding metalloenzymes and ligands, the excavation and expansion of metalloenzyme-specific knowledge will thus be of great utility, not only in understanding and investigating metalloenzyme science (e.g. functions and ligand associations), but also in promoting and bridging metalloenzyme-related areas, including the design of non-protein metal using catalysts.</p>
    <p>Previously, we established a metalloenzyme-ligand association database called MeLAD, with the aim of providing a general metalloenzyme-platform, in particular to assist metalloenzyme drug discovery (<xref rid="B13" ref-type="bibr">13</xref>). MeLAD provides centralized information exclusive to metalloenzyme-ligand associations, uniquely including excavated metal-binding pharmacophores (MBPs) and deduced metalloenzyme-ligand associations. Here, we reveal the integrated Metallo<italic toggle="yes">e</italic>nzyme Data Bank and Analysis platform, termed MeDBA (<ext-link xlink:href="https://medba.ddtmlab.org" ext-link-type="uri">https://medba.ddtmlab.org</ext-link>), which has a wider scope of metalloenzyme-specific knowledges and services. In MeDBA, metalloenzymes are divided into three general categories: M-I, M-II and M-III. M-I enzyme metal ions are directly involved in catalysis and are tightly bound at the active site, M-II enzyme metal ions are directly involved in catalysis, but are not tightly bound in active site, and M-III enzyme metal ions are important for enzyme activity, but are not present in active site. These metalloenzyme classifications will guide different objectives in metalloenzyme research, e.g. metal-binding drug discovery and <italic toggle="yes">de novo</italic> design of metalloenzymes. Comprehensive information on metalloenzymes, including names, catalytic reaction, and family, is provided by MeDBA. In particular, the overall profiles of metalloenzymes according to super-families and diseases are displayed, information which might help establish new research topics and open unexploited fields. Metalloenzyme structural information (e.g. metal sites and ligand interactions), together with substrates and bioactive molecules (e.g. PROTAC ligands, macrocycles, spiro compounds, drugs, and drug candidates) are comprehensively presented in an easy-to-use, cross-association manner. Importantly, MeDBA uniquely provides elaborately excavated MBPs for searching and servers for structure/metal active site comparisons and metalloenzyme profiling. New forms of webpage displays and interactive functions (e.g. structural comparisons, MBPs, and interaction display) are developed, which may be used as references for development of other database and web servers.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Metalloenzyme identification</title>
      <p>We began with data analysis of Protein Data Bank (PDB) structures (186,521 structures, available on 1 May 2022) using MeCOM, a tool for metal site detection and comparison (<xref rid="B14" ref-type="bibr">14</xref>). In MeCOM, the metal ions or metal-containing cofactors and corresponding chelating residues are defined as metal sites. Given a PDB structure, MeCOM detects an inferred metalloenzyme <italic toggle="yes">via</italic> the following steps: detecting all the metal sites in a structure; detecting whether any of the metal sites are adjacent to a potential active site pocket or a ligand within 6 Å; if yes, labelling the structure as ‘inferred metalloenzyme; recording the corresponding metal site contents including metal site composition, coordination mode, ligands, and pharmacophore files (for later ‘metal active site comparison’). To this end, 33 023 metal sites were extracted and 8790 proteins (with unique UniProt identifiers) were labelled as inferred metalloenzymes. Non-enzymatic proteins were then excluded according to UniProt information, leading to a list of 5836 inferred metalloenzymes with 25 160 corresponding metal sites.</p>
      <p>We then manually curated all these inferred metalloenzymes and classified them into three general categories (M-I, M-II and M-III) by structure visualization and reference checking. Category M-I enzyme metal ions are directly involved in catalysis and are (apparently) tightly bound at the active site, M-II enzyme metal ions are directly involved in catalysis, but are not tightly bound at the active site, and M-III enzyme metal ions are important for enzyme activity (e.g. by stabilizing structural stability), but are not present at the active site. This process resulted in identification of 4722 metalloenzymes (3685 M-I metalloenzymes, 333 M-II metalloenzymes, and 704 M-III metalloenzymes) with corresponding 21 616 metal sites.</p>
      <p>In addition to above described structure sources, we performed keyword searching in UniProt (<xref rid="B15" ref-type="bibr">15</xref>) and BRENDA (<xref rid="B16" ref-type="bibr">16</xref>) to identify potential metalloenzymes that were not successfully identified by MeCOM, or metalloenzymes which have no reported 3D structures, including uncharacterized metalloenzymes. In UniProt, keywords such as ‘metalloenzyme’ and ‘metallo*ase’, and metal binding information annotated with ‘catalytic’, were queried and filtered by organisms, which led to a list of 10,071 reviewed metalloenzymes and 54,301 unreviewed metalloenzymes. In BRENDA, the keywords (e.g. ‘require’, ‘depend’, ‘catalyze’, ‘metalloenzyme’ and ‘metalloprotease’) were queried specially for the enzymes with the ‘Metals/Ions’ records, which resulted in a list of 3,142 metalloenzymes. All these entries were manually reviewed and clustered in terms of catalytic metals, metal dependence, protein names, protein families and corresponding references. To this end, 46 927 metalloenzymes were retained.</p>
      <p>According to all above-obtained metalloenzymes, we summarized a series of confidently assigned metalloenzyme families, such as metallo-β-lactamases, matrix metalloproteinases and 2-oxoglutarate-dependent oxygenases, which guided us to exploitation of metalloenzyme data from other free databases (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). Finally, we combined all the source data and removed duplicated entries (according to the UniProt identifier), then assigned metalloenzyme categories by referring to structural and family information. In total, 82,540 unique metalloenzymes were retained in MeDBA, consisting of 74 267 M-I metalloenzymes, 7338 M-II metalloenzymes and 935 M-III metalloenzymes.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Metalloenzyme information collection and process</title>
      <p>To provide comprehensive information for above-obtained metalloenzymes, we first collected basic information, including protein name, gene name, organism, protein family, enzyme commission (EC) number, catalytic reaction, biofunction, and cofactor if present from UniProt. The families of metalloenzymes were collected from InterPro (<xref rid="B19" ref-type="bibr">19</xref>), which were used for the hierarchical family tree display. Metalloenzyme related disease data were collected from TTD (<xref rid="B20" ref-type="bibr">20</xref>) and ChEMBL (version 29) (<xref rid="B21" ref-type="bibr">21</xref>), and grouped by ICD-11 (<xref rid="B22" ref-type="bibr">22</xref>) and MeSH disease taxonomy, respectively. The distribution specificity data, such as tissue specificity, single cell type specificity, and brain specificity, were collected from ProteinAtlas (<xref rid="B23" ref-type="bibr">23</xref>). DNA/RNA binding metalloenzymes were identified by three sources: keywords (‘DNA-binding’ or ‘RNA-binding’) in UniProt, structural information from NPIDB (<xref rid="B24" ref-type="bibr">24</xref>), and RNA-binding protein annotations from RBP2GO (<xref rid="B25" ref-type="bibr">25</xref>). Intrinsically disordered metalloenzymes were annotated according to information from DisProt (<xref rid="B26" ref-type="bibr">26</xref>).</p>
      <p>Metalloenzyme structure relevant information was then collected. Protein sequences were retrieved from UniProt (<xref rid="B15" ref-type="bibr">15</xref>), and protein domains were from InterPro (<xref rid="B19" ref-type="bibr">19</xref>). All experimental and predicted structures of metalloenzymes were collected from the PDB (<xref rid="B27" ref-type="bibr">27</xref>) and AlphaFoldDB (<xref rid="B28" ref-type="bibr">28</xref>), respectively. Notably, all metal site information, including metal site composition, coordination features, potential active pockets and nearby ligands, were generated using MeCOM (<xref rid="B14" ref-type="bibr">14</xref>); these metal sites were further grouped to metal site classes according to the metal ions and nature of the metal chelation.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Ligand identification and process</title>
      <p>To sufficiently obtain metalloenzyme ligands, we considered different data sources. We first retrieved bioactive molecules for metalloenzymes from BindingDB (<xref rid="B29" ref-type="bibr">29</xref>) and ChEMBL (<xref rid="B21" ref-type="bibr">21</xref>). We then retrieved and curated drug/drug candidate information including mechanism of action, drug type, indication and maximum clinical phase, from TTD (<xref rid="B20" ref-type="bibr">20</xref>), ChEMBL (<xref rid="B21" ref-type="bibr">21</xref>) and recent references. Metalloenzyme-mediated reactions and corresponding substrates/products were collected from the Rhea database (<xref rid="B30" ref-type="bibr">30</xref>). Metalloenzyme-targeted PROTAC ligands were collected from PROTAC-DB (<xref rid="B31" ref-type="bibr">31</xref>). Notably, ligands from metalloprotein-ligand complex structures were collected separately. Finally, standard ‘InChI’ identifiers (<xref rid="B32" ref-type="bibr">32</xref>) were calculated for all the collected ligands, which guided removal of the duplicates and assignment of unique IDs (e.g. MeLig00000001) for all ligands. A total of 440 631 metalloenzyme-related ligands were included in MeDBA.</p>
      <p>To provide more properties for browsing/searching ligands, we calculated the following properties: molecular weight, number of hydrogen bond acceptors, number of hydrogen bond donors, number of rotatable bonds, number of aromatic rings, topological polar surface area (TPSA), and ClogP by using RDKit tools. Notably, special ligands such as macrocycles (i.e. compounds containing a ring that consists of 12 or more atoms) and spiro compounds (i.e. containing at least one spiro atom) were analysed using RDKit. The SMILES string and MOL format files are available for all ligands.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Metalloenzyme-ligand association data collection and analysis</title>
      <p>To better understand metalloenzyme-ligand associations, MeDBA provides 3D visualization of metalloenzymes complexed with ligands, proteins and DNAs/RNAs, and core metal binding pharmacophores (MBPs). The metalloenzyme–ligand complex structures were analysed by MeCOM (<xref rid="B14" ref-type="bibr">14</xref>) and related ligand information was extracted. The structures, UniProt ID and corresponding chains of metalloenzyme-binding proteins were collected from PDBe-KB (<xref rid="B33" ref-type="bibr">33</xref>). The metalloenzyme–DNA/RNA complexes were collected from NPIDB (<xref rid="B24" ref-type="bibr">24</xref>). Since MBPs are of great significance to drug discovery, we analysed all metalloenzyme-ligand complex structures in detail to obtain MBPs by the following steps: detecting the ligand metal-chelating atoms according to the rules of metal coordination as defined in AncPhore (<xref rid="B34" ref-type="bibr">34</xref>); labelling the metal-chelating atoms; (ii) splitting the ligand into fragments according to the bond cleavage rules as defined in LEADOPT (<xref rid="B35" ref-type="bibr">35</xref>); (iii) using the Floyd–Warshall algorithm (<xref rid="B36" ref-type="bibr">36</xref>) based shortest path algorithm to connect all the fragments if containing metal-chelating atoms, with the aim of defining an intact MBP for each metalloenzyme-ligand complex. Eventually, a total of 844 unique MBPs were obtained.</p>
    </sec>
    <sec id="SEC2-5">
      <title>Metalloenzyme-specific analysis servers</title>
      <p>To conveniently use the metalloenzyme data bank, we provided metalloenzyme-specific analysis servers. The 3D visualization of structure and interactions are provided using 3DMol (<xref rid="B37" ref-type="bibr">37</xref>), and the detailed views of protein-ligand interactions are supported by PLIP (<xref rid="B38" ref-type="bibr">38</xref>). The substructure search, conducted by OpenBabel (<xref rid="B39" ref-type="bibr">39</xref>), is designed for ligand and MBP searches. The structure and metal site comparison analyses employ MICAN (<xref rid="B40" ref-type="bibr">40</xref>) and MeCOM (<xref rid="B14" ref-type="bibr">14</xref>) for hind computations, respectively. Moreover, a ligand similarity server, implemented by OpenBabel (<xref rid="B39" ref-type="bibr">39</xref>), is provided for metalloenzyme profiling and for identification of new metalloenzyme-ligand associations.</p>
    </sec>
    <sec id="SEC2-6">
      <title>Database implementation</title>
      <p>MeDBA was developed using Python (version 3.9.12) and the Flask web framework (version 2.0.3), which runs on a Linux server (CentOS v7.04) with Nginx (version 1.20.1) and uWSGI (version 2.020) as the web servers, and the MySQL Community 8.0 as the database server. The user-friendly web interface is based on Bootstrap (version 4.61) and jQuery (version 3.60). Echarts (version 5.3) is exploited to provide intuitive statistical views of the data. Visualizations of the metalloenzyme-related 3D structures views and the chemical structures of ligands are supported by 3DMol (<xref rid="B37" ref-type="bibr">37</xref>) and RDKit, respectively. JSME is used to provide online molecular search service (<xref rid="B41" ref-type="bibr">41</xref>). API is used for data exchange, and asynchronous request and browser cache are utilized to increase data transmission efficiency and guarantee a better global service. The MeDBA website is <ext-link xlink:href="http://HTTPS" ext-link-type="uri">HTTPS</ext-link>-enabled, which ensures that the data exchange between users and MeDBA servers is secured by an encrypted connection. MeDBA is freely accessible without registration and optimized for Google Chrome, Windows Edge, MacOS Safari, Opera and Firefox.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>DATABASE CONTENT AND FEATURES</title>
    <sec id="SEC3-1">
      <title>MeDBA overview</title>
      <p>MeDBA aims to provide an integrated, distinctive, practicable, user-friendly platform for metalloenzyme-focused data and analysis. MeDBA contains three main sections: ‘Metalloenzymes’, ‘Ligands’ and ‘Metalloenzyme–Ligand Associations’ (Figure <xref rid="F1" ref-type="fig">1</xref>). The ‘Metalloenzymes’ section involves comprehensive metalloenzyme information, including metalloenzyme category, catalytic activity, expression, family, disease, structure, metal site, and related servers. The ‘Ligand’ section contains metalloenzyme substrates/products and bioactive molecules, in which special ligands (e.g. PROTAC ligands, macrocycles and spiro compounds), drugs and drug candidates are highlighted. The ‘Metalloenzyme–Ligand Associations’ section mainly involves detailed interactions of metalloenzyme–ligand, –protein and –DNA/RNA complexes, elaborately excavated MBPs, and related servers, facilitating to understand the association principles and derive new metalloenzyme-ligand associations. Related resources, help materials, and visit statistics are available. The current version of MeDBA contains data on 82 540 metalloenzymes (74 267 M-I metalloenzymes, 7338 M-II metalloenzymes and 935 M-III metalloenzymes), 440 631 ligands (431 014 bioactive molecules, 2243 substrates/products, 566 drugs, 6942 drug candidates and 1415 PROTACs), 10 613 metalloenzyme-ligand complexes, 21 616 metal sites and 844 MBPs.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of MeDBA resources. The numbers in parentheses refer to the number of entries in the current version.</p>
        </caption>
        <graphic xlink:href="gkac860fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Metalloenzymes</title>
      <p>The Metalloenzyme menu gives direct access to the comprehensive metalloenzyme information and analysis modules. By using ‘<italic toggle="yes">Metalloenzyme Statistics</italic>’, users can quickly view basic information on metalloenzyme statistics (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). On the ‘<italic toggle="yes">Metalloenzyme Search</italic>’ page, users can retrieve all metalloenzyme entries and corresponding information <italic toggle="yes">via</italic> nine kinds of annotations, including metalloenzyme name, gene name, metal ion, and metal site class. The retrieved results can be filtered by metalloenzyme category, enzyme class, and metal ion/metal-containing cofactor; they can be linked to the original data resources by clicking on the blue arrow or further accessed to the detail page for a specific metalloenzyme <italic toggle="yes">via</italic> UniProt ID (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>). The metalloenzyme detail page contains basic information (e.g. category, enzyme name, gene name, family, EC number, biofunction, cofactor, catalytic activity, expression, and disease), structural information (e.g. metalloenzyme sequence, InterPro domain, 3D structure, and metal site), and ligand information (e.g. chemical structure, source, association type, and association content) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figures S3 and S4</xref>).</p>
      <p>In order to enable users to explore overall metalloenzyme families and their involvement in disease, metalloenzyme-family and metalloenzyme-disease associations are displayed in a hierarchical tree structure. On the ‘<italic toggle="yes">Metalloenzyme Families</italic>’ page, users can click or search a metalloenzyme family to obtain descriptions regarding the family and relevant metalloenzyme entries, along with corresponding categories and UniProt IDs. This tool is helpful for investigating biofunctions or catalytic mechanisms, including for uncharacterized metalloenzymes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S5</xref>). On the ‘<italic toggle="yes">Metalloenzyme Diseases</italic>’ page, metalloenzyme-related diseases are exhibited in ICD-11 or MeSH disease taxonomy, and can be filtered by keywords (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S6</xref>). Users can obtain information regarding metalloenzymes related to a specific disease, a function that will be beneficial in drug discovery, in particular when targeting multiple metalloenzymes or in studies aimed at improving ligand selectivity.</p>
      <p>Given the unique characteristics of metalloenzymes, their structures are of special interest. As described above, the assigned metalloenzyme structures were analysed using MeCOM (<xref rid="B14" ref-type="bibr">14</xref>), and further manually curated into three categories: M-I, M-II and M-III. The metalloenzyme categories are useful to guide investigations on metal ion-involved interactions (e.g. ligand discovery). Currently, MeDBA contains 50 892 structures, covering 4205 M-I, 1342 M-II and 779 M-III metalloenzymes. The ‘<italic toggle="yes">Structure</italic>’ page supports searches by PDB code, metalloenzyme name, metal ion, metal-containing cofactor, and ligand code, and enables the user to obtain detailed structure information (e.g. 3D structure, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S7</xref>) by clicking on the PDB code or details of metalloenzyme information by UniProt ID. All the metalloenzyme structures were analysed to generate separate metal binding sites, which were then grouped with the focus on metal ions and metal chelates. A total of 1738 metal site classes were obtained, which can be searched using the ‘<italic toggle="yes">Metal Site</italic>’ page (Figure <xref rid="F2" ref-type="fig">2A</xref>). Users can obtain a list of metalloenzymes for each metal site class, which groups the same or highly similar metal sites, and can access detailed structural information (Figure <xref rid="F2" ref-type="fig">2B</xref>–<xref rid="F2" ref-type="fig">D</xref>). The metal site information will be useful both for metalloenzyme identification and <italic toggle="yes">de novo</italic> design.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>The metal site search, visualization, and comparison modules. (<bold>A</bold>) View of metal site classes, metal chelates, and relevant metalloenzymes in the ‘<italic toggle="yes">Metal Site</italic>’ page, which supports searching, internal and external linking. (<bold>B</bold>) View of related metalloenzymes when clicking the metal site class ‘msc_01575’. (<bold>C</bold>) View of detailed metal site information for PDB code 1UZE. (<bold>D</bold>) 3D visualization of angiotensin-converting enzyme's metal site. (<bold>E</bold>) Task panel of the ‘<italic toggle="yes">Metal Active Site Comparison</italic>’ module. (<bold>F</bold>) 3D visualization of the aligned metal sites for angiotensin-converting enzyme isoforms (reference metal site from PDB code 1R4L; query metal site from PDB code 1UZE).</p>
        </caption>
        <graphic xlink:href="gkac860fig2" position="float"/>
      </fig>
      <p>To further exploit metalloenzyme structural information, we introduced two structural analysis modules (<italic toggle="yes">i.e</italic>. structure and metal active site comparison) in MeDBA. The ‘<italic toggle="yes">Structure Superimposition</italic>’ module enables users to compare metalloenzyme structures by superimpositions. By selecting two metalloenzyme structures and clicking the ‘Submit’ button, users can obtain calculated similarity scores and visualize the aligned metalloenzyme structures using the 3D graphical interface; users are also able to download the aligned structures for local analysis. By comparison, the ‘<italic toggle="yes">Metal Active Site Comparison</italic>’ module enables users to gain deeper insight into metal active site similarity by using MeCOM (<xref rid="B14" ref-type="bibr">14</xref>). Users can select two kinds of superimposition modes (i.e. ‘metal/alpha-C atoms’ and ‘pharmacophore’) for metal active site comparison (Figure <xref rid="F2" ref-type="fig">2E</xref>), and can obtain aligned metal active sites and the similarity score in a few seconds. Notably, this 3D graphical interface enables users to visualize the surface residues and binding pockets adjacent to the metal active site; moreover, the cartoon representations of the protein can be optionally switched off to focus on the aligned metal active sites (Figure <xref rid="F2" ref-type="fig">2F</xref>).</p>
      <p>Special types of metalloenzymes, including DNA/RNA-binding and disordered metalloenzymes, are displayed individually in the Metalloenzyme section. The ‘<italic toggle="yes">DNA/RNA-binding metalloenzymes</italic>’ page contains the basic information (e.g. name, category, and UniProt ID), nucleic acid types (DNA, RNA, and Hybrid) and related experimental structures, and supports users to search, browse and download. The collected intrinsically disordered metalloenzymes are listed on the ‘<italic toggle="yes">Disordered Metalloenzymes</italic>’ page, where users can obtain basic information, including disordered sequences.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Ligands</title>
      <p>The Ligands section holds general information for bioactive molecules interacting with metalloenzymes and metalloenzyme substrates/products. The ‘<italic toggle="yes">Ligand Statistics</italic>’ page gives an overall view of ligand information (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figures S8 and S9</xref>). Users can retrieve ligand information (e.g. chemical structures, information contents and basic properties) by querying a metalloenzyme name or UniProt ID on the ‘<italic toggle="yes">Ligand Search</italic>’ page. The Ligands section also supports chemical structure searches by inputting a SMILES or drawing a structure in the JSME applet window, an option which is valuable for users to quickly find ligands containing a given substructure or core scaffold (Figure <xref rid="F3" ref-type="fig">3A</xref>). The information contents (e.g. ‘Drug’ and ‘Macrocycle’) and ligand properties can be utilized as filter options to narrow search results. Through the ligand ID, users can access to the detailed ligand page, which gives basic properties, structure information and metalloenzyme association contents (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S10</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Ligand searching. (<bold>A</bold>) View of ligand structures, metalloenzymes, and the information content in the ‘<italic toggle="yes">Ligand Search</italic>’ module, exemplified by a substructure search with 1-cyclopropylethan-1-one (SMILES: CC(=O)C1CC1). (<bold>B</bold>) View of metalloenzyme-mediated reactions and related substrates and products, with an example of graphic showing the reaction equation for Rhea ID 10389.</p>
        </caption>
        <graphic xlink:href="gkac860fig3" position="float"/>
      </fig>
      <p>On the ‘<italic toggle="yes">Bioactive Molecules</italic>’ page, users can obtain bioactivity data (‘IC<sub>50</sub>’, ‘EC<sub>50</sub>’, ‘<italic toggle="yes">K</italic><sub>i</sub>’ or ‘<italic toggle="yes">K</italic><sub>d</sub>’) and original references by searching a metalloenzyme name or UniProt ID (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S11</xref>); the search results can be filtered by metalloenzyme category, assay type and activity source. The ‘<italic toggle="yes">Substrates/Products</italic>’ page contains metalloenzyme-mediated reactions and corresponding substrates/products, which users can search, view and download (Figure <xref rid="F3" ref-type="fig">3B</xref>). To improve the user experience, both graphical and textual reaction equations are provided. In addition, ligands of special interest including PROTACs, macrocycles, and spiro compounds, are provided in independent pages. For example, on the ‘<italic toggle="yes">PROTACs</italic>’ page, users can retrieve the PROTAC name, the relevant E3 ligase, bioassay data, source reference and related metalloenzymes by metalloenzyme name or UniProt ID. Identified macrocycles and spiro compounds are listed along with their chemical structures and bioactivity records, if available, on the ‘<italic toggle="yes">Macrocycles</italic>’ page and ‘<italic toggle="yes">Spiro Compounds</italic>’ page, respectively.</p>
      <p>Data on drugs and drug candidates are important for metalloenzyme-targeted medicinal chemistry, and these are summarized on the ‘<italic toggle="yes">Approved Drugs</italic>’ and ‘<italic toggle="yes">Agents in Clinical Trials</italic>’ pages, respectively. Users can obtain information regarding drug name, chemical structure, metalloenzyme target category, metalloenzyme name, drug type, mechanism of action, clinical indication, and current clinical phase. The scope of drugs/drug candidates can be narrowed down by filtering metalloenzyme category, drug type and mechanism of action (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S12</xref>). Notably, clicking a specific clinical indication will navigate to the corresponding ‘<italic toggle="yes">Metalloenzyme Diseases</italic>’ page for detailed information.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Metalloenzyme-ligand associations</title>
      <p>This section of MeDBA involves structural bioinformation, MBP and metalloenzyme profiling modules, aiming to inform on the principles of metalloenzyme-ligand associations and to inspire or predict new metalloenzyme-ligand associations. Reported metalloenzyme-ligand complexes are listed on the ‘<italic toggle="yes">Metalloenzyme–Ligand Interactions</italic>’ page, which enables users to search by PDB code, metalloenzyme name, UniProt ID, ligand code and metal ions; interactions can be visualized in the graphical window by clicking the ‘3D view’ button (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S13</xref>). The ‘<italic toggle="yes">Metalloenzyme–Protein Interactions</italic>’ and ‘<italic toggle="yes">Metalloenzyme–DNA/RNA Interactions</italic>’ pages are provided for users to analyse how metalloenzymes interact with proteins and nucleic acids, which may be useful for understanding roles of metalloenzymes in signal transduction beyond catalysis.</p>
      <p>The ‘<italic toggle="yes">MBP Search’</italic> module, in which a total of 844 excavated MBPs are displayed, not only enables links between different metalloenzymes to be made, but also provide clues to establish new metalloenzyme-ligand associations. Users can click a MBP chemical structure to obtain details of its metalloenzyme-ligand associations (ligand structure and interaction visualization, Figure <xref rid="F4" ref-type="fig">4A</xref>). Users can also search by substructure to identify related MBPs and metalloenzyme–ligand associations.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Metal-binding pharmacophore (MBP) and metalloenzyme profiling modules. (<bold>A</bold>) View of MBPs listed in ‘<italic toggle="yes">MPB Search</italic>’ module and corresponding detailed information through clicking on the MBP0576 chemical structure. (<bold>B</bold>) View of task panel of the ‘<italic toggle="yes">Profiling by Ligand Similarity</italic>’ module, with an example of metalloenzyme profiling for the queried compound ‘3,4-dihydro-2H-benzo[e][1,2]oxaborinin-2-ol’, resulting in top-ranked similar ligands and their metalloenzyme associations.</p>
        </caption>
        <graphic xlink:href="gkac860fig4" position="float"/>
      </fig>
      <p>The ‘<italic toggle="yes">Profiling by Ligand Similarity</italic>’ module provides a web server to predict potential metalloenzyme-ligand associations on the basis of ligand chemical similarity. Users can query a small molecule of interest by drawing its chemical structure, inputting SMILES or uploading a mol2/sdf format file, then setting up profiling parameters including database range (metalloenzyme category subsets or the entire database), similarity approach (‘FP2’, ‘FP3’, ‘FP4’ or ‘MACCS’), and similarity cutoff (Figure <xref rid="F4" ref-type="fig">4B</xref>). After submitting the job, users can obtain results within a few seconds, then can visualize ranked similar ligands and corresponding metalloenzymes (e.g. metalloenzyme categories, bioactivity records, complex structures, and references) (Figure <xref rid="F4" ref-type="fig">4B</xref>). Notably, the module is an efficient and convenient way to compare binding modes and MBP chemotypes.</p>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>SUMMARY AND FUTURE DIRECTIONS</title>
    <p>MeDBA comprehensively integrates information regarding metalloenzymes, their ligands, metalloenzyme-ligand associations with metalloenzyme-specific computational analysis tools. It is the first database to provide general metalloenzyme categories based on approximate metal ion coordination strength and whether or not the metal ions are involved in catalysis. Importantly, MeDBA not only provides metalloenzyme bioactive molecules and substrates, but also provides experimentally determined metalloenzyme–ligand, –protein and –DNA/RNA complex structures as well as elaborately excavated metal-binding pharmacophores, information which will be important basis for deriving new metalloenzyme-related associations. The powerful yet simple to use analysis tools of MeDBA facilitate the retrieval, browsing, and querying of metalloenzymes and associated information, promoting information use and communication. Despite these features, we think there is still space for improvement and development of MeDBA, e.g. by expansion of MBPs, inclusion of metallo-ribozymes and DNAzymes, and improved analysis of metalloenzyme profiling. We intend MeDBA will serve as a valuable platform, coupled with advances in interface of chemistry, biology, and medicine, to foster research in the multifaceted field of metalloenzymes.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC5">
    <title>DATA AVAILABILITY</title>
    <p>MeDBA, help materials and related tools/resources are freely available at <ext-link xlink:href="https://medba.ddtmlab.org" ext-link-type="uri">https://medba.ddtmlab.org</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkac860_Supplemental_File</label>
      <media xlink:href="gkac860_supplemental_file.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkac860#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>National Natural Science Foundation of China [82122065, 82073698, 81874291 to G.B.L.], Sichuan Science and Technology Program [2022YFH0027 to G.B.L.]; 111 Project [B18035]; C.J.S. thank Cancer Research UK and the Biotechnological and Biological Research Council for support. Funding for open access charge: National Natural Science Foundation of China [82122065].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. No conflicts are declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Stockwell</surname><given-names>B.R.</given-names></string-name>, <string-name><surname>Conrad</surname><given-names>M.</given-names></string-name></person-group><article-title>Ferroptosis: mechanisms, biology and role in disease</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><year>2021</year>; <volume>22</volume>:<fpage>266</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">33495651</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahlson</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Dixon</surname><given-names>S.J.</given-names></string-name></person-group><article-title>Copper-induced cell death</article-title>. <source>Science</source>. <year>2022</year>; <volume>375</volume>:<fpage>1231</fpage>–<lpage>1232</lpage>.<pub-id pub-id-type="pmid">35298241</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sigel</surname><given-names>R.K.O.</given-names></string-name>, <string-name><surname>Pyle</surname><given-names>A.M.</given-names></string-name></person-group><article-title>Alternative roles for metal ions in enzyme catalysis and the implications for ribozyme chemistry</article-title>. <source>Chem. Rev.</source><year>2007</year>; <volume>107</volume>:<fpage>97</fpage>–<lpage>113</lpage>.<pub-id pub-id-type="pmid">17212472</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hemschemeier</surname><given-names>A.</given-names></string-name>, <string-name><surname>Happe</surname><given-names>T.</given-names></string-name></person-group><article-title>The plasticity of redox cofactors: from metalloenzymes to redox-active DNA</article-title>. <source>Nat. Rev. Chem.</source><year>2018</year>; <volume>2</volume>:<fpage>231</fpage>–<lpage>243</lpage>.</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wittwer</surname><given-names>M.</given-names></string-name>, <string-name><surname>Markel</surname><given-names>U.</given-names></string-name>, <string-name><surname>Schiffels</surname><given-names>J.</given-names></string-name>, <string-name><surname>Okuda</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sauer</surname><given-names>D.F.</given-names></string-name>, <string-name><surname>Schwaneberg</surname><given-names>U.</given-names></string-name></person-group><article-title>Engineering and emerging applications of artificial metalloenzymes with whole cells</article-title>. <source>Nat. Catal.</source><year>2021</year>; <volume>4</volume>:<fpage>814</fpage>–<lpage>827</lpage>.</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vornholt</surname><given-names>T.</given-names></string-name>, <string-name><surname>Christoffel</surname><given-names>F.</given-names></string-name>, <string-name><surname>Pellizzoni</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Panke</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Jeschek</surname><given-names>M.</given-names></string-name></person-group><article-title>Systematic engineering of artificial metalloenzymes for new-to-nature reactions</article-title>. <source>Sci. Adv.</source><year>2021</year>; <volume>7</volume>:<fpage>eabe4208</fpage>.<pub-id pub-id-type="pmid">33523952</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fedorov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Beknazarov</surname><given-names>N.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gautam</surname><given-names>A.</given-names></string-name>, <string-name><surname>Williams</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>J.C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis</article-title>. <source>Nature</source>. <year>2022</year>; <volume>606</volume>:<fpage>594</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">35614224</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barreira da Silva</surname><given-names>R.</given-names></string-name>, <string-name><surname>Leitao</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Pechuan-Jorge</surname><given-names>X.</given-names></string-name>, <string-name><surname>Werneke</surname><given-names>S.</given-names></string-name>, <string-name><surname>Oeh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Javinal</surname><given-names>V.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Phung</surname><given-names>W.</given-names></string-name>, <string-name><surname>Everett</surname><given-names>C.</given-names></string-name>, <string-name><surname>Nonomiya</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity</article-title>. <source>Nat. Immun.</source><year>2022</year>; <volume>23</volume>:<fpage>568</fpage>–<lpage>580</lpage>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>A.Y.</given-names></string-name>, <string-name><surname>Adamek</surname><given-names>R.N.</given-names></string-name>, <string-name><surname>Dick</surname><given-names>B.L.</given-names></string-name>, <string-name><surname>Credille</surname><given-names>C.V.</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>C.N.</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>S.M.</given-names></string-name></person-group><article-title>Targeting metalloenzymes for therapeutic intervention</article-title>. <source>Chem. Rev.</source><year>2019</year>; <volume>119</volume>:<fpage>1323</fpage>–<lpage>1455</lpage>.<pub-id pub-id-type="pmid">30192523</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riccardi</surname><given-names>L.</given-names></string-name>, <string-name><surname>Genna</surname><given-names>V.</given-names></string-name>, <string-name><surname>De Vivo</surname><given-names>M.</given-names></string-name></person-group><article-title>Metal–ligand interactions in drug design</article-title>. <source>Nat. Rev. Chem.</source><year>2018</year>; <volume>2</volume>:<fpage>100</fpage>–<lpage>112</lpage>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>Y.-H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name></person-group><article-title>Principles and current strategies targeting metallo-β-lactamase mediated antibacterial resistance</article-title>. <source>Med. Res. Rev.</source><year>2020</year>; <volume>40</volume>:<fpage>1558</fpage>–<lpage>1592</lpage>.<pub-id pub-id-type="pmid">32100311</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname><given-names>Y.-C.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>J.-L.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Q.-Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name></person-group><article-title>Targeting metalloenzymes by boron-containing metal-binding pharmacophores</article-title>. <source>J. Med. Chem.</source><year>2021</year>; <volume>64</volume>:<fpage>17706</fpage>–<lpage>17727</lpage>.<pub-id pub-id-type="pmid">34875836</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Su</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Y.-H.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.-Y.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Q.-Q.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>X.-L.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>C.-L.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>C.</given-names></string-name>, <string-name><surname>McDonough</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Schofield</surname><given-names>C.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>MeLAD: an integrated resource for metalloenzyme-ligand associations</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>904</fpage>–<lpage>909</lpage>.<pub-id pub-id-type="pmid">31504189</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Q.-Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name></person-group><article-title>MeCOM: a method for comparing three-dimensional metalloenzyme active sites</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>; <volume>62</volume>:<fpage>730</fpage>–<lpage>739</lpage>.<pub-id pub-id-type="pmid">35044164</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Consortium</surname><given-names>T.U.</given-names></string-name></person-group><article-title>UniProt: the universal protein knowledgebase in 2021</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D480</fpage>–<lpage>D489</lpage>.</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>A.</given-names></string-name>, <string-name><surname>Jeske</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ulbrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hofmann</surname><given-names>J.</given-names></string-name>, <string-name><surname>Koblitz</surname><given-names>J.</given-names></string-name>, <string-name><surname>Schomburg</surname><given-names>I.</given-names></string-name>, <string-name><surname>Neumann-Schaal</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jahn</surname><given-names>D.</given-names></string-name>, <string-name><surname>Schomburg</surname><given-names>D.</given-names></string-name></person-group><article-title>BRENDA, the ELIXIR core data resource in 2021: new developments and updates</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D498</fpage>–<lpage>D508</lpage>.</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naas</surname><given-names>T.</given-names></string-name>, <string-name><surname>Oueslati</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bonnin</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Dabos</surname><given-names>M.L.</given-names></string-name>, <string-name><surname>Zavala</surname><given-names>A.</given-names></string-name>, <string-name><surname>Dortet</surname><given-names>L.</given-names></string-name>, <string-name><surname>Retailleau</surname><given-names>P.</given-names></string-name>, <string-name><surname>Iorga</surname><given-names>B.I.</given-names></string-name></person-group><article-title>Beta-lactamase database (BLDB) – structure and function</article-title>. <source>J. Enzy. Inh. Med. Chem.</source><year>2017</year>; <volume>32</volume>:<fpage>917</fpage>–<lpage>919</lpage>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Y.-H.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name></person-group><article-title>ProfKin: a comprehensive web server for structure-based kinase profiling</article-title>. <source>Eur. J. Med. Chem.</source><year>2021</year>; <volume>225</volume>:<fpage>113772</fpage>.<pub-id pub-id-type="pmid">34411891</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blum</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>H.-Y.</given-names></string-name>, <string-name><surname>Chuguransky</surname><given-names>S.</given-names></string-name>, <string-name><surname>Grego</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kandasaamy</surname><given-names>S.</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>A.</given-names></string-name>, <string-name><surname>Nuka</surname><given-names>G.</given-names></string-name>, <string-name><surname>Paysan-Lafosse</surname><given-names>T.</given-names></string-name>, <string-name><surname>Qureshi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The interpro protein families and domains database: 20 years on</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D344</fpage>–<lpage>D354</lpage>.</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>F.</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name></person-group><article-title>Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>; <volume>50</volume>:<fpage>D1398</fpage>–<lpage>D1407</lpage>.</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendez</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bento</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>De Veij</surname><given-names>M.</given-names></string-name>, <string-name><surname>Félix</surname><given-names>E.</given-names></string-name>, <string-name><surname>Magariños</surname><given-names>MaríaP.</given-names></string-name>, <string-name><surname>Mosquera</surname><given-names>JuanF.</given-names></string-name>, <string-name><surname>Mutowo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M</given-names></string-name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res</source>. <year>2018</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>The</surname><given-names>L.</given-names></string-name></person-group><article-title>icd-11</article-title>. <source>Lancet</source>. <year>2019</year>; <volume>393</volume>:<fpage>2275</fpage>.<pub-id pub-id-type="pmid">31180012</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uhlén</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fagerberg</surname><given-names>L.</given-names></string-name>, <string-name><surname>Hallström</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Lindskog</surname><given-names>C.</given-names></string-name>, <string-name><surname>Oksvold</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mardinoglu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sivertsson</surname><given-names>Å.</given-names></string-name>, <string-name><surname>Kampf</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sjöstedt</surname><given-names>E.</given-names></string-name>, <string-name><surname>Asplund</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Tissue-based map of the human proteome</article-title>. <source>Science</source>. <year>2015</year>; <volume>347</volume>:<fpage>1260419</fpage>.<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zanegina</surname><given-names>O.</given-names></string-name>, <string-name><surname>Kirsanov</surname><given-names>D.</given-names></string-name>, <string-name><surname>Baulin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Karyagina</surname><given-names>A.</given-names></string-name>, <string-name><surname>Alexeevski</surname><given-names>A.</given-names></string-name>, <string-name><surname>Spirin</surname><given-names>S.</given-names></string-name></person-group><article-title>An updated version of NPIDB includes new classifications of DNA–protein complexes and their families</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>; <volume>44</volume>:<fpage>D144</fpage>–<lpage>D153</lpage>.<pub-id pub-id-type="pmid">26656949</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caudron-Herger</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>R.E.</given-names></string-name>, <string-name><surname>Wassmer</surname><given-names>E.</given-names></string-name>, <string-name><surname>Diederichs</surname><given-names>S.</given-names></string-name></person-group><article-title>RBP2GO: a comprehensive pan-species database on RNA-binding proteins, their interactions and functions</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D425</fpage>–<lpage>D436</lpage>.</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quaglia</surname><given-names>F.</given-names></string-name>, <string-name><surname>Mészáros</surname><given-names>B.</given-names></string-name>, <string-name><surname>Salladini</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hatos</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pancsa</surname><given-names>R.</given-names></string-name>, <string-name><surname>Chemes</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Pajkos</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>T.</given-names></string-name>, <string-name><surname>Peña-Díaz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DisProt in 2022: improved quality and accessibility of protein intrinsic disorder annotation</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>; <volume>50</volume>:<fpage>D480</fpage>–<lpage>D487</lpage>.</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burley</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Bhikadiya</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bittrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Crichlow</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Christie</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Dalenberg</surname><given-names>K.</given-names></string-name>, <string-name><surname>Di Costanzo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>J.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>RCSB protein data bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D437</fpage>–<lpage>D451</lpage>.</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Anyango</surname><given-names>S.</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.</given-names></string-name>, <string-name><surname>Natassia</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yordanova</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Stroe</surname><given-names>O.</given-names></string-name>, <string-name><surname>Wood</surname><given-names>G.</given-names></string-name>, <string-name><surname>Laydon</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>; <volume>50</volume>:<fpage>D439</fpage>–<lpage>D444</lpage>.</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilson</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Baitaluk</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nicola</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Chong</surname><given-names>J.</given-names></string-name></person-group><article-title>BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>; <volume>44</volume>:<fpage>D1045</fpage>–<lpage>D1053</lpage>.<pub-id pub-id-type="pmid">26481362</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bansal</surname><given-names>P.</given-names></string-name>, <string-name><surname>Morgat</surname><given-names>A.</given-names></string-name>, <string-name><surname>Axelsen</surname><given-names>K.B.</given-names></string-name>, <string-name><surname>Muthukrishnan</surname><given-names>V.</given-names></string-name>, <string-name><surname>Coudert</surname><given-names>E.</given-names></string-name>, <string-name><surname>Aimo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Hyka-Nouspikel</surname><given-names>N.</given-names></string-name>, <string-name><surname>Gasteiger</surname><given-names>E.</given-names></string-name>, <string-name><surname>Kerhornou</surname><given-names>A.</given-names></string-name>, <string-name><surname>Neto</surname><given-names>T.B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Rhea, the reaction knowledgebase in 2022</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>; <volume>50</volume>:<fpage>D693</fpage>–<lpage>D700</lpage>.</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weng</surname><given-names>G.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X.</given-names></string-name>, <string-name><surname>He</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>T.</given-names></string-name></person-group><article-title>PROTAC-DB: an online database of PROTACs</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>49</volume>:<fpage>D1381</fpage>–<lpage>D1387</lpage>.</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heller</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>McNaught</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pletnev</surname><given-names>I.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>S.</given-names></string-name>, <string-name><surname>Tchekhovskoi</surname><given-names>D</given-names></string-name></person-group><article-title>InChI, the IUPAC international chemical identifier</article-title>. <source>J. Cheminform.</source><year>2015</year>; <volume>7</volume>:<fpage>23</fpage>.<pub-id pub-id-type="pmid">26136848</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>consortium</surname><given-names>P.-K.</given-names></string-name></person-group><article-title>PDBe-KB: a community-driven resource for structural and functional annotations</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>; <volume>48</volume>:<fpage>D344</fpage>–<lpage>D353</lpage>.</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dai</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ning</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name></person-group><article-title>AncPhore: a versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo-β-lactamases and indoleamine/tryptophan 2,3-dioxygenases</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2021</year>; <volume>11</volume>:<fpage>1931</fpage>–<lpage>1946</lpage>.<pub-id pub-id-type="pmid">34386329</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G.-B.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.-L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>R.-J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.-Y.</given-names></string-name></person-group><article-title>LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors</article-title>. <source>Eur. J. Med. Chem.</source><year>2015</year>; <volume>93</volume>:<fpage>523</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">25743214</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Floyd</surname><given-names>R.W.</given-names></string-name></person-group><article-title>Algorithm 97: Shortest path</article-title>. <source>Commun. ACM</source>. <year>1962</year>; <volume>5</volume>:<fpage>345</fpage>.</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rego</surname><given-names>N.</given-names></string-name>, <string-name><surname>Koes</surname><given-names>D</given-names></string-name></person-group><article-title>3Dmol.js: molecular visualization with WebGL</article-title>. <source>Bioinformatics</source>. <year>2014</year>; <volume>31</volume>:<fpage>1322</fpage>–<lpage>1324</lpage>.<pub-id pub-id-type="pmid">25505090</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adasme</surname><given-names>M.F.</given-names></string-name>, <string-name><surname>Linnemann</surname><given-names>K.L.</given-names></string-name>, <string-name><surname>Bolz</surname><given-names>S.N.</given-names></string-name>, <string-name><surname>Kaiser</surname><given-names>F.</given-names></string-name>, <string-name><surname>Salentin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Haupt</surname><given-names>VJ.</given-names></string-name>, <string-name><surname>Schroeder</surname><given-names>M.</given-names></string-name></person-group><article-title>PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>; <volume>49</volume>:<fpage>W530</fpage>–<lpage>W534</lpage>.<pub-id pub-id-type="pmid">33950214</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Boyle</surname><given-names>N.M.</given-names></string-name>, <string-name><surname>Banck</surname><given-names>M.</given-names></string-name>, <string-name><surname>James</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Morley</surname><given-names>C.</given-names></string-name>, <string-name><surname>Vandermeersch</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hutchison</surname><given-names>G.R.</given-names></string-name></person-group><article-title>Open babel: an open chemical toolbox</article-title>. <source>J. Cheminform.</source><year>2011</year>; <volume>3</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Minami</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sawada</surname><given-names>K.</given-names></string-name>, <string-name><surname>Chikenji</surname><given-names>G.</given-names></string-name></person-group><article-title>MICAN: a protein structure alignment algorithm that can handle Multiple-chains, inverse alignments, C(α) only models, alternative alignments, and non-sequential alignments</article-title>. <source>BMC Bioinform</source>. <year>2013</year>; <volume>14</volume>:<fpage>24</fpage>.</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bienfait</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ertl</surname><given-names>P.</given-names></string-name></person-group><article-title>JSME: a free molecule editor in javascript</article-title>. <source>J. Cheminform.</source><year>2013</year>; <volume>5</volume>:<fpage>24</fpage>.<pub-id pub-id-type="pmid">23694746</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
